SynthesisThoracic cancer2017
Overexpression of NRF2 is correlated with prognoses of patients with malignancies: A meta-analysis.
Synthesis in Thoracic cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 40 citations in OpenAlex.
- FGFR2-triggered autophagy and activation of Nrf-2 reduce breast cancer cell response to anti-ER drugs.Cellular & molecular biology letters · 2024Article
- Redox-state-regulating enzymes have prognostic value in diabetic endometrial cancer patients: impact of statin use?Frontiers in oncology · 2024Article
- The Involvement of Peroxiporins and Antioxidant Transcription Factors in Breast Cancer Therapy Resistance.Cancers · 2023Review
- The nuclear factor erythroid 2-related factor 2/p53 axis in breast cancer.Biochemia medica · 2023Review
- Stapled Peptides as Direct Inhibitors of Nrf2-sMAF Transcription Factors.Journal of medicinal chemistry · 2023Article
- Cannabidiol Inhibits Tumorigenesis in Cisplatin-Resistant Non-Small Cell Lung Cancer via TRPV2.Cancers · 2022Article
- The Expression and Prognostic Value of Cancer Stem Cell Markers, NRF2, and Its Target Genes in TAE/TACE-Treated Hepatocellular Carcinoma.Medicina (Kaunas, Lithuania) · 2022Article
- Nuclear Factor Erythroid 2-related Factor 2 Knockout Suppresses the Development of Aggressive Colorectal Cancer Formation Induced by Azoxymethane/Dextran Sulfate Sodium-Treatment in Female Mice.Journal of cancer prevention · 2021Article
- RETRACTED: Identification of Redox-Sensitive Transcription Factors as Markers of Malignant Pleural Mesothelioma.Cancers · 2021Article
- The Clinicopathological and Prognostic Significance of Nrf2 and Keap1 Expression in Hepatocellular Carcinoma.Cancers · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious published research has demonstrated that NRF2 expression is a poor prognostic factor for many malignancies. However, because of the small sample enrolled in a single study, it is difficult to draw valuable conclusions. Therefore, we hypothesized that NRF2 overexpression in cancer tissues may be associated with the prognoses of patients with solid malignancies, and conducted a systemic review and meta-analysis.
methodsA comprehensive search of PubMed, Web of Science, Science Direct, Embase, and Ovid databases for relevant studies regarding the role of NRF2 expression in solid malignancies was conducted. Hazard ratios (HR) and 95% confidence intervals (CIs) were extracted from these studies to provide pooled estimates of the effect of NRF2 expression on patients' overall and disease-free survival.
resultsNine studies met the criteria for analysis. Statistical analysis demonstrated that compared to patients with low NRF2 expression, patients with overexpression of NRF2 had poorer overall survival (HR 2.01, 95% CI 1.57-2.56; P < 0.001) and disease-free survival (HR 3.25, 95% CI 1.29-8.15; P = 0.025).
conclusionPublished evidence of the role of NRF2 expression in survival of cancer patients is limited. This analysis supports the view that NRF2 overexpression is a poor prognostic factor for solid malignancies, thus optimizing treatment for patients with NRF2 overexpression may improve their overall survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.